Q3 2024
BUSINESS UPDATE

NOVEMBER 4, 2024

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA

Q3 2024 UPDATE

We are executing on our key priorities.

Internal Programs & Pipeline

Clinical Trial Application (CTA) for **ABCL635** anticipated in Q2 2025

Clinical Trial Application (CTA) for **ABCL575** anticipated in Q2 2025

Advancing portfolio of programs in discovery, including wholly-owned and 50/50 co-development programs

Engine & Capabilities

Moved into new headquarters, which was initiated in 2020

In the final stages of building our capabilities and facilities including: our **GMP manufacturing facility** and expansion of our core team for **translational science** and **clinical operations**

Strategic Partnerships

Building on co-development collaborations

Engaging with existing and new partners on our **TCE platform**

Q3 2024

FINANCIALS UPDATE

COPYRIGHT © ABCELLERA

Continued progress on key business metrics and a strong cash position.

~$875M in available liquidity to execute on our strategy

~$670M in total cash, cash equivalents, & marketable securities

95 cumulative partner-initiated program starts with downstreams

14 molecules in the clinic

2 internal programs advanced into IND-enabling studies

COPYRIGHT © ABCELLERA

Continuing portfolio growth.

Cumulative # of

PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS



Cumulative # of

MOLECULES IN THE CLINIC



Notable Updates on

Molecule	This Quarter's Update
ABD-147	New: received orphan-disease designation

Note: Showing year-end figures, except for most-recent quarter. Historical results are not necessarily indicative of future results.

COPYRIGHT © ABCELLERA

Operating expenses reflect ongoing investments, predominantly in R&D; partly offset by $7M in revenue.

Revenue USD



Operating Expenses USD



COPYRIGHT © ABCELLERA

Net loss of $51M; equivalent to ($0.17) per share (basic & diluted).

Earnings USD





COPYRIGHT © ABCELLERA

Approximately $670M in total cash, equivalents, and marketable securities.

Cash Flows USD



* Restricted cash (including restricted cash in other assets)

COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA